Patent US5567720A successfully refreshed from Google Patents.
← Back to Patent Explorer
US5567720A Expired / Lapsed US ⏱️ 0.0 years remaining

Pharmaceutically active agents that impede amyloid formation in vivo

Assignee: DMS Pharmaceutical Inc
•
Filing: 1994-06-27
•
Granted: 1996-10-22
•
Expires: 2014-06-27
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Dense microspheres can be extracted and purified to substantial homogeneity from mammalian brain tissue, and used in the screening of therapies for potential effectiveness in impeding the formation of amyloid fibrils associated with Alzheimer's disease and other forms of cerebral amyloidosis. Compounds that, at in-tissue concentrations of 10 -5 M or less, inhibit amyloid formation in a test animal injected intracerebrally with dense microspheres are particularly useful in inhibiting treating cerebral amyloidosis.

Inventors

  • 👤 Paul Averback

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-09 14:20
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/68; G01N33/6893; G01N33/6896; A; A61; A61K; A61K31/00; A61K31/33; A61K31/335; A61K31/35; A61K31/395; A61K31/40; A61K31/41; A61K31/42; A61K31/495; A61K31/505; A61K31/55; A61K31/63; A61K31/655; A61K31/70; C; C07; C07H; C07H17/00; C07H17/04; C07H17/08; C07H19/00; C07H19/02; C07H19/04; C07H19/06; G01N33/5005; G01N33/5008; G01N33/5082; G01N33/5088; G01N2333/00; G01N2333/435; G01N2333/46; G01N2333/47; G01N2333/4701; G01N2333/4709; G01N2500/00; G01N2800/00; G01N2800/28; G01N2800/2814; G01N2800/2821; Y; Y10; Y10S; Y10S436/00; Y10S436/811; Y10S530/00; Y10S530/827; Y10S530/839

Claims Analysis

Total Claims: 8
Claim 1
Independent Claim 59 words
A method of treating cerebral amyloidosis, comprising the step of administering to a subject, in whom amyloid formation is anticipated, a pharmaceutically effective amount of a compound that inhibits formation of amyloid fibrils when administered, at an in-tissue concentration of about 10 -5 M or less, to a test animal that has received an intracerebral injection of dense microspheres.
Claim 2
Independent Claim 59 words
A method of treating cerebral amyloidosis, comprising the step of administering to a subject, in whom amyloid formation is anticipated, a pharmaceutically effective amount of a compound that inhibits formation of amyloid fibrils when administered, at an in-tissue concentration of about 10 -5 M or less, to a test animal that has received an intracerebral injection of dense microspheres.
Claim 3
Dependent Claim 37 words
A method according to claim 1, wherein said compound inhibits formation of amyloid fibrils by acting on DMS components such that a structural transition of DMS protein in the brain to a β-pleated sheet conformation is prevented.
Claim 4
Dependent Claim 27 words
A method according to claim 1, wherein said subject does not display clinical or other evidence indicative of Alzheimer's disease or dementia associated with another disease state.
Claim 5
Dependent Claim 24 words
A method according to claim 3, wherein said administering prevents a decline in brain function in said subject, said decline being short of dementia.
Claim 6
Dependent Claim 34 words
A method according to claim 1, wherein symptoms of dementia are not evident in said subject but said subject tests positive for increased risk of Alzheimer's disease or dementia due to another disease state.
Claim 7
Dependent Claim 19 words
A method according to claim 5, wherein said subject tests positive for presence of DMS disruption in the brain.
Claim 8
Dependent Claim 29 words
A method according to claim 1, wherein said compound is selected from the group consisting of pyrimethamine, cromolyn sodium, erythromycin, purpurogallin, tartrazine, sulfanilamide, benzopurpurine 4B, 29H,31H-phthalocyanine, 5-methyl-2-thiouridine and 1,2-benzlsoxazole.

References Cited (Backward Citations)

No citation records indexed.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1999-10-22 2000-04-22 2000-10-22 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2003-10-22 2004-04-22 2004-10-22 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2007-10-22 2008-04-22 2008-10-22 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag